Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 3

NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

,

Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.

EP. 1: Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
EP. 2: Concurrent NSCLC Biomarker Testing at Diagnosis
Now Viewing
EP. 3: NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
EP. 4: Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
EP. 5: Biomarker Testing in Early-Stage NSCLC
EP. 6: Reflex Testing for Patients with Suspected Lung Cancer
EP. 7: Challenges of NSCLC Biomarker Testing in Clinical Practice
EP. 8: Overcoming Barriers to NSCLC Biomarker Testing
EP. 9: Key Takeaways for Concurrent Biomarker Testing in NSCLC

Related Content:

Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker TestingThe US Oncology NetworkLung CancerOncLive News Network®
Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting
Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing